1n8z

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor, receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4, (ERBB4). ErbB receptors are essential mediators of cell proliferation and, differentiation in the developing embryo and in adult tissues, and their, inappropriate activation is associated with the development and severity, of many cancers. Overexpression of HER2 is found in 20-30% of human breast, cancers, and correlates with more aggressive tumours and a poorer, prognosis. Anticancer therapies targeting ErbB receptors have shown, promise, and a monoclonal antibody against HER2, Herceptin (also known as, trastuzumab), is currently in use as a treatment for breast cancer. Here, we report crystal structures of the entire extracellular regions of rat, HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding, fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for, HER2 that resembles a ligand-activated state, and show HER2 poised to, interact with other ErbB receptors in the absence of direct ligand, binding. Herceptin binds to the juxtamembrane region of HER2, identifying, this site as a target for anticancer therapies.
+
HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.
==Disease==
==Disease==
Line 17: Line 17:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Transferase]]
[[Category: Transferase]]
-
[[Category: Cho, H.S.]]
+
[[Category: Cho, H S.]]
-
[[Category: Gabelli, S.B.]]
+
[[Category: Gabelli, S B.]]
-
[[Category: Jr., D.W.Denney.]]
+
[[Category: Jr., D W.Denney.]]
-
[[Category: Leahy, D.J.]]
+
[[Category: Leahy, D J.]]
[[Category: Mason, K.]]
[[Category: Mason, K.]]
-
[[Category: Ramyar, K.X.]]
+
[[Category: Ramyar, K X.]]
-
[[Category: Stanley, A.M.]]
+
[[Category: Stanley, A M.]]
[[Category: NAG]]
[[Category: NAG]]
[[Category: SO4]]
[[Category: SO4]]
Line 29: Line 29:
[[Category: tyrosin kinase receptor]]
[[Category: tyrosin kinase receptor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:27:43 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:03:33 2008''

Revision as of 12:03, 21 February 2008


1n8z, resolution 2.52Å

Drag the structure with the mouse to rotate

Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab

Contents

Overview

HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.

Disease

Known diseases associated with this structure: Adenocarcinoma of lung, somatic OMIM:[164870], Gastric cancer, somatic OMIM:[164870], Glioblastoma, somatic OMIM:[164870], Ovarian cancer, somatic, OMIM:[164870], Sialidosis, type I OMIM:[608272], Sialidosis, type II OMIM:[608272]

About this Structure

1N8Z is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Transferase, with EC number and 2.7.10.2 2.7.10.1 and 2.7.10.2 Full crystallographic information is available from OCA.

Reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab., Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ, Nature. 2003 Feb 13;421(6924):756-60. PMID:12610629

Page seeded by OCA on Thu Feb 21 14:03:33 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools